207 related articles for article (PubMed ID: 26226845)
1. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Wang Y; Stevenson HS; Edelman DC; Meltzer PS; Barr FG
Mod Pathol; 2015 Sep; 28(9):1214-24. PubMed ID: 26226845
[TBL] [Abstract][Full Text] [Related]
2. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
3. Gene Co-Expression Networks Restructured Gene Fusion in Rhabdomyosarcoma Cancers.
Helm BR; Zhan X; Pandya PH; Murray ME; Pollok KE; Renbarger JL; Ferguson MJ; Han Z; Ni D; Zhang J; Huang K
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31480361
[TBL] [Abstract][Full Text] [Related]
4. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
[TBL] [Abstract][Full Text] [Related]
5. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
6. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
7. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
9. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
[TBL] [Abstract][Full Text] [Related]
10. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
11. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
[TBL] [Abstract][Full Text] [Related]
12. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
13. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case.
Gordon A; McManus A; Anderson J; Fisher C; Abe S; Nojima T; Pritchard-Jones K; Shipley J
Cancer Genet Cytogenet; 2003 Jan; 140(1):73-7. PubMed ID: 12550764
[TBL] [Abstract][Full Text] [Related]
14. Detection of PAX3/PAX7-FKHR fusion transcripts in rhabdomyosarcoma and other small round cell tumors by 1-step reverse transcriptase polymerase chain reaction: a novel tool for diagnosis and differentiation.
Yang XL; Zhang SC; Zhang SW; Wang H
Ann Diagn Pathol; 2012 Apr; 16(2):107-11. PubMed ID: 22197543
[TBL] [Abstract][Full Text] [Related]
15. Upstream CpG island methylation of the PAX3 gene in human rhabdomyosarcomas.
Kurmasheva RT; Peterson CA; Parham DM; Chen B; McDonald RE; Cooney CA
Pediatr Blood Cancer; 2005 Apr; 44(4):328-37. PubMed ID: 15602708
[TBL] [Abstract][Full Text] [Related]
16. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
[TBL] [Abstract][Full Text] [Related]
17. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
19. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH; Mercado GE; Laé M; Ladanyi M
Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
[TBL] [Abstract][Full Text] [Related]
20. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
